Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 9/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1949475 | 0.91 | HPGD (0.56) | MEN1KMT2ANPSR1NPC1SMN1; SMN2 | |
| SCHEMBL6323472 | 0.91 | MEN1 (0.48) | MEN1KMT2ANPSR1NPC1SMN1; SMN2 | |
| SCHEMBL3767269 | 0.89 | TMEM97 (0.47) | MEN1KMT2ANPSR1NPC1SMN1; SMN2 | |
| SCHEMBL5592397 | 0.88 | TMEM97 (0.47) | MEN1KMT2ANPSR1NPC1SMN1; SMN2 | |
| SCHEMBL5592390 | 0.85 | TMEM97 (0.46) | MEN1KMT2ANPSR1NPC1SMN1; SMN2 | |
| SCHEMBL19960792 | 0.85 | SMN1; SMN2 (0.45) | MEN1KMT2ANPSR1NPC1SMN1; SMN2 | |
| SCHEMBL5592283 | 0.84 | MEN1 (0.52) | MEN1KMT2ANPSR1NPC1SMN1; SMN2 | |
| SCHEMBL5592314 | 0.83 | MEN1 (0.51) | MEN1KMT2ANPSR1NPC1SMN1; SMN2 | |
| SCHEMBL4743828 | 0.83 | GRIN2B (0.49) | MEN1KMT2ANPSR1NPC1SMN1; SMN2 | |
| SCHEMBL955547 | 0.82 | MEN1 (0.55) | MEN1KMT2ANPSR1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44205-E1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-7067655-B2 | preparation of furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl, phenyl, pyrrolyl or C4-C6 cycloalkenyl- substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosines prepared from 2-amino-4,6-dihydroxypyrimidine, POCl3 and dimethylformamide | SCHERING CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-6897216-B2 | Adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1283839-B1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20050026932-A1 | Adenosine A2a receptor antagonists | SCHERING CORPORATION | 2005-02-03 | — | — | US | disclosed |
| US-20040023997-A1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. | 2004-02-05 | — | — | US | disclosed |
| US-6630475-B2 | 5-amino-pyrazolo-(4, 3-e)-1,2,4-triazolo(1,5-c)pyrimidine adenosine A2a receptor antagonists; use in the treatment of central nervous system diseases, in particular Parkinson's disease | SCHERING CORPORATION | 2003-10-07 | — | — | US | disclosed |
| EP-1283839-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-02-19 | — | — | EP | disclosed |
| US-20020099061-A1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-07-25 | — | — | US | disclosed |
| WO-2001092264-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026932-A1 | Adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA2B | MEN1 3974/4885KMT2A 2140/4885NPSR1 37/4885 |
| US-20020099061-A1 | Adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA2B | MEN1 4567/4885KMT2A 2255/4885NPSR1 103/4885 |
| US-20040023997-A1 | Adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA2B | MEN1 4573/4885KMT2A 2285/4885NPSR1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.